DiaMedica Selling General Administrative vs Operating Income Analysis

DMAC Stock

USD 4.70 0.52 12.44%

DiaMedica Therapeutics financial indicator trend analysis is much more than just examining DiaMedica Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether DiaMedica Therapeutics is a good investment. Please check the relationship between DiaMedica Therapeutics Selling General Administrative and its Operating Income accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.

Selling General Administrative vs Operating Income

Selling General Administrative vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of DiaMedica Therapeutics Selling General Administrative account and Operating Income. At this time, the significance of the direction appears to have pay attention.

The correlation between DiaMedica Therapeutics' Selling General Administrative and Operating Income is -0.98. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Operating Income in the same time period over historical financial statements of DiaMedica Therapeutics, assuming nothing else is changed. The correlation between historical values of DiaMedica Therapeutics' Selling General Administrative and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of DiaMedica Therapeutics are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Selling General Administrative i.e., DiaMedica Therapeutics' Selling General Administrative and Operating Income go up and down completely randomly.

Correlation Coefficient

-0.98

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Selling General Administrative

Operating Income

Operating Income is the amount of profit realized from DiaMedica Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of DiaMedica Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from DiaMedica Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into DiaMedica Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.At present, DiaMedica Therapeutics' Tax Provision is projected to increase significantly based on the last few years of reporting.

	2023	2024 (projected)
Reconciled Depreciation	28K	21.7K
Interest Income	44.9K	47.1K

Reconciled Depreciation Interest Income

DiaMedica Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Other Current Assets	Net Tangible Assets	Property Plant Equipment	Capital Surpluse	Current Deferred Revenue	Non Current Liabilities Total
Total Assets		-0.27	0.79	0.78	1.0	0.83	-0.36	-0.92	0.18	0.34	-0.06	-0.38	1.0	0.34	0.96	0.97	0.78	0.88	1.0	0.19	0.83	0.99	0.83	0.92	0.24	-0.22
Short Long Term Debt Total	-0.27		-0.06	0.0	-0.28	-0.1	0.46	0.19	0.19	-0.46	0.4	0.34	-0.28	-0.51	-0.23	-0.22	0.04	-0.12	-0.29	-0.09	-0.21	-0.29	-0.06	-0.48	0.15	0.86
Other Current Liab	0.79	-0.06		0.86	0.78	0.83	-0.26	-0.81	0.1	0.24	-0.14	-0.08	0.79	0.41	0.83	0.88	0.85	0.85	0.79	-0.11	0.74	0.78	0.85	0.76	0.41	0.03
Total Current Liabilities	0.78	0.0	0.86		0.76	0.8	-0.16	-0.79	0.54	0.14	-0.3	-0.03	0.79	0.23	0.81	0.84	0.99	0.82	0.79	0.11	0.71	0.78	0.81	0.72	0.39	0.11
Total Stockholder Equity	1.0	-0.28	0.78	0.76		0.82	-0.37	-0.92	0.16	0.35	-0.05	-0.39	1.0	0.34	0.96	0.97	0.77	0.87	1.0	0.19	0.83	0.99	0.83	0.92	0.23	-0.24
Property Plant And Equipment Net	0.83	-0.1	0.83	0.8	0.82		-0.22	-0.89	0.15	0.21	-0.09	0.04	0.83	0.35	0.93	0.88	0.85	0.99	0.83	0.25	0.75	0.87	0.98	0.83	0.21	0.02
Net Debt	-0.36	0.46	-0.26	-0.16	-0.37	-0.22		0.28	0.04	-1.0	0.02	0.06	-0.35	-0.72	-0.25	-0.35	-0.13	-0.21	-0.36	0.26	-0.58	-0.36	-0.17	-0.48	-0.15	0.47
Retained Earnings	-0.92	0.19	-0.81	-0.79	-0.92	-0.89	0.28		-0.18	-0.27	0.2	0.25	-0.93	-0.34	-0.97	-0.95	-0.82	-0.92	-0.93	-0.22	-0.78	-0.93	-0.88	-0.9	-0.1	0.24
Accounts Payable	0.18	0.19	0.1	0.54	0.16	0.15	0.04	-0.18		-0.03	-0.24	0.06	0.19	-0.22	0.16	0.2	0.51	0.15	0.19	0.12	0.13	0.19	0.11	0.14	0.26	0.26
Cash	0.34	-0.46	0.24	0.14	0.35	0.21	-1.0	-0.27	-0.03		-0.03	-0.06	0.33	0.71	0.24	0.33	0.12	0.19	0.34	-0.22	0.56	0.35	0.15	0.47	0.14	-0.46
Non Current Assets Total	-0.06	0.4	-0.14	-0.3	-0.05	-0.09	0.02	0.2	-0.24	-0.03		0.21	-0.11	-0.15	-0.14	-0.08	-0.29	-0.09	-0.11	-0.39	-0.07	-0.13	-0.06	-0.2	0.16	0.34
Non Currrent Assets Other	-0.38	0.34	-0.08	-0.03	-0.39	0.04	0.06	0.25	0.06	-0.06	0.21		-0.39	0.07	-0.24	-0.3	0.0	-0.03	-0.39	-0.06	-0.11	-0.38	0.04	-0.31	-0.06	0.36
Cash And Short Term Investments	1.0	-0.28	0.79	0.79	1.0	0.83	-0.35	-0.93	0.19	0.33	-0.11	-0.39		0.33	0.96	0.97	0.79	0.88	1.0	0.21	0.83	0.99	0.83	0.92	0.23	-0.23
Net Receivables	0.34	-0.51	0.41	0.23	0.34	0.35	-0.72	-0.34	-0.22	0.71	-0.15	0.07	0.33		0.35	0.38	0.23	0.34	0.34	-0.13	0.46	0.32	0.33	0.54	0.17	-0.48
Common Stock Shares Outstanding	0.96	-0.23	0.83	0.81	0.96	0.93	-0.25	-0.97	0.16	0.24	-0.14	-0.24	0.96	0.35		0.97	0.84	0.96	0.96	0.25	0.8	0.97	0.93	0.93	0.2	-0.18
Other Stockholder Equity	0.97	-0.22	0.88	0.84	0.97	0.88	-0.35	-0.95	0.2	0.33	-0.08	-0.3	0.97	0.38	0.97		0.84	0.91	0.97	0.06	0.82	0.97	0.87	0.94	0.32	-0.19
Total Liab	0.78	0.04	0.85	0.99	0.77	0.85	-0.13	-0.82	0.51	0.12	-0.29	0.0	0.79	0.23	0.84	0.84		0.87	0.79	0.21	0.72	0.79	0.86	0.73	0.38	0.15
Property Plant And Equipment Gross	0.88	-0.12	0.85	0.82	0.87	0.99	-0.21	-0.92	0.15	0.19	-0.09	-0.03	0.88	0.34	0.96	0.91	0.87		0.88	0.25	0.79	0.91	0.99	0.85	0.22	-0.01
Total Current Assets	1.0	-0.29	0.79	0.79	1.0	0.83	-0.36	-0.93	0.19	0.34	-0.11	-0.39	1.0	0.34	0.96	0.97	0.79	0.88		0.21	0.83	0.99	0.83	0.92	0.23	-0.24
Short Term Debt	0.19	-0.09	-0.11	0.11	0.19	0.25	0.26	-0.22	0.12	-0.22	-0.39	-0.06	0.21	-0.13	0.25	0.06	0.21	0.25	0.21		0.02	0.24	0.23	0.16	-0.35	0.02
Other Current Assets	0.83	-0.21	0.74	0.71	0.83	0.75	-0.58	-0.78	0.13	0.56	-0.07	-0.11	0.83	0.46	0.8	0.82	0.72	0.79	0.83	0.02		0.82	0.8	0.75	0.19	-0.18
Net Tangible Assets	0.99	-0.29	0.78	0.78	0.99	0.87	-0.36	-0.93	0.19	0.35	-0.13	-0.38	0.99	0.32	0.97	0.97	0.79	0.91	0.99	0.24	0.82		0.86	0.93	0.22	-0.21
Property Plant Equipment	0.83	-0.06	0.85	0.81	0.83	0.98	-0.17	-0.88	0.11	0.15	-0.06	0.04	0.83	0.33	0.93	0.87	0.86	0.99	0.83	0.23	0.8	0.86		0.79	0.2	0.04
Capital Surpluse	0.92	-0.48	0.76	0.72	0.92	0.83	-0.48	-0.9	0.14	0.47	-0.2	-0.31	0.92	0.54	0.93	0.94	0.73	0.85	0.92	0.16	0.75	0.93	0.79		0.28	-0.41
Current Deferred Revenue	0.24	0.15	0.41	0.39	0.23	0.21	-0.15	-0.1	0.26	0.14	0.16	-0.06	0.23	0.17	0.2	0.32	0.38	0.22	0.23	-0.35	0.19	0.22	0.2	0.28		0.35
Non Current Liabilities Total	-0.22	0.86	0.03	0.11	-0.24	0.02	0.47	0.24	0.26	-0.46	0.34	0.36	-0.23	-0.48	-0.18	-0.19	0.15	-0.01	-0.24	0.02	-0.18	-0.21	0.04	-0.41	0.35

Click cells to compare fundamentals

DiaMedica Therapeutics Account Relationship Matchups

DiaMedica Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	9.1M	28.1M	45.6M	34.4M	54.2M	56.9M
Short Long Term Debt Total	178K	118K	52K	469K	400K	276.0K
Other Current Liab	1.1M	791K	917K	1.3M	1.7M	1.8M
Total Current Liabilities	1.3M	2.0M	1.5M	2.2M	2.8M	2.9M
Total Stockholder Equity	7.6M	26.0M	44.0M	31.8M	51.1M	53.6M
Property Plant And Equipment Net	217K	174K	112K	560K	485K	509.3K
Net Debt	(3.7M)	(7.3M)	(4.7M)	(4.3M)	(4.1M)	(4.4M)
Retained Earnings	(56.6M)	(68.9M)	(82.5M)	(96.2M)	(115.6M)	(109.8M)
Accounts Payable	182K	1.1M	509K	734K	926K	563.1K
Cash	3.9M	7.4M	4.7M	4.7M	4.5M	3.5M
Non Current Assets Total	217K	174K	112K	560K	485K	638.8K
Non Currrent Assets Other	217K	100K	(40.4M)	(1.0)	(0.9)	(0.94)
Cash And Short Term Investments	7.9M	27.5M	45.1M	33.5M	52.9M	55.5M
Net Receivables	823K	340K	130K	82K	369K	387.5K
Common Stock Shares Outstanding	12.0M	15.7M	20.8M	26.4M	32.6M	34.2M
Liabilities And Stockholders Equity	9.1M	28.1M	45.6M	34.4M	54.2M	56.9M
Other Stockholder Equity	64.2M	94.9M	126.6M	128.1M	166.6M	174.9M
Total Liab	1.4M	2.1M	1.5M	2.6M	3.1M	3.3M
Property Plant And Equipment Gross	217K	174K	179K	560K	585K	614.3K
Total Current Assets	8.8M	27.9M	45.4M	33.8M	53.7M	56.4M
Accumulated Other Comprehensive Income	2K	(2K)	(51K)	(74K)	6K	5.7K
Short Term Debt	60K	130K	98K	138K	166K	90.0K
Other Current Assets	47K	74K	197K	251K	411K	431.6K
Net Tangible Assets	17.0M	7.6M	26.0M	44.0M	50.6M	53.2M
Short Term Investments	4.0M	20.1M	40.4M	28.8M	48.4M	50.8M
Property Plant Equipment	217K	74K	112K	560K	644K	676.2K
Capital Surpluse	41.0M	63.0M	64.2M	94.9M	109.2M	114.6M
Non Current Liabilities Total	118K	53K	3K	400K	317K	158.5K
Capital Lease Obligations	178K	118K	52K	469K	400K	420K
Net Invested Capital	7.6M	26.0M	44.0M	31.8M	51.1M	28.0M
Net Working Capital	7.5M	25.9M	43.9M	31.7M	50.9M	27.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:

How To Invest In DiaMedica

Details

Is DiaMedica Stock a good investment?

Details

What is DiaMedica Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.

You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.56)

Return On Assets

(0.24)

Return On Equity

(0.35)

The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

DiaMedica Selling General Administrative vs Operating Income Analysis

Selling General Administrative vs Operating Income

Selling General Administrative vs Operating Income Correlation Analysis

Correlation Coefficient

Selling General Administrative

Operating Income

DiaMedica Therapeutics fundamental ratios Correlations

DiaMedica Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

DiaMedica Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 1.0	Net Debt
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Net Tangible Assets	- 0.93	Retained Earnings
Total Current Assets	- 0.93	Retained Earnings
Cash And Short Term Investments	- 0.93	Retained Earnings